Loading…
Brief Report - Extended Interval between Enzyme Therapy Infusions for Adult Patients with Gaucher's Disease Type 1
BACKGROUND: Enzyme replacement therapy (ERT) for Gaucher's disease with alglucerase or imiglucerase is efficacious, well-tolerated and safe. However, cost considerations, visits to medical facilities, potentially duration of theray for life, are issues of major concern to a proportion of treate...
Saved in:
Published in: | Journal of postgraduate medicine (Bombay) 2003-08, Vol.49 (2) |
---|---|
Main Author: | |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | BACKGROUND: Enzyme replacement therapy (ERT) for Gaucher's disease with
alglucerase or imiglucerase is efficacious, well-tolerated and safe.
However, cost considerations, visits to medical facilities, potentially
duration of theray for life, are issues of major concern to a
proportion of treated patients and has, in some cases, led to the
withdrawal of therapy. AIMS: To elucidate whether an extension of the
interval between enzyme infusions to once every three weeks is as
effective in maintaining the clinical responses achieved with the
bi-monthly regimen. MATERIALS AND METHODS: Four patients with an
optimal response to ERT (at 30 units/kg every two weeks for an average
of 27 months), were subjected to enzyme dose/frequency changes that
essentially constituted a reduction in cumulative dose over the
treatment period. Patients were assessed every 6 months for alterations
in haematological parameters, plasma chitotriosidase levels, liver and
spleen size, and bone symptoms. RESULTS: All patients had to resume the
previous infusion schedule of once every two weeks; one because of new
bone marrow infiltrates, two because of visceral enlargement, and the
fourth due to progressive anaemia. CONCLUSIONS: This limited experience
suggests that a reduction in enzyme dose associated with an extended
interval between infusions may lead to variable disease control, and
underscores the need for individualization of enzyme therapy. (J
Postgrad Med 2003;49:127-131) |
---|---|
ISSN: | 0022-3859 |